News
New cancer drugs may have saved more than 1.2 million Americans
Cancer drugs approved between 2000 and 2016 significantly reduced deaths from the most common cancers in the United States.
News
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
News
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
News
Study supports multigene panel testing for all breast cancer patients with second primary cancers
The results could lead to better implementation of cancer prevention and screening strategies, according to researchers.
News
Peripheral blood MRD correlates with treatment benefit in CLL
CHICAGO—Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory...
News
Interim PET scans identify HL patients with better outcomes
CHICAGO—Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after...
News
Chemo-free combo provides potential first-line option for FL
CHICAGO—A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus...
News
Pomalidomide triplet significantly extends PFS in R/R MM
CHICAGO—The addition of pomalidomide to bortezomib and low‐dose dexamethasone (PVd) significantly improves progression-free survival (PFS) in...
News
Once-weekly carfilzomib combo improves PFS in R/R MM
CHICAGO—A once-weekly regimen of carfilzomib plus dexamethasone shows a favorable benefit-risk profile for patients with relapsed or refractory (R...
News
Team develops new scoring systems for PMF
ATLANTA—Two novel prognostic scoring systems can help clinicians decide how to treat certain patients with primary myelofibrosis (PMF), according...
News
Allo-HSCT leads to long-term survival in MF
ATLANTA—One of the largest single-center studies of fludarabine/melphalan-based allogeneic hematopoietic stem cell transplant (allo-HSCT) for...
News
Ruxolitinib improves survival for MF patients in CP-e
ATLANTA—A new study suggests the JAK2 inhibitor ruxolitinib has the potential to significantly improve survival in patients who have chronic phase...
News
Neurotoxicity needs separate treatment from CRS in CAR T-cell therapy
CHICAGO – The neurotoxicity in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL) treated with CD19 CAR T cells...
News
CAR T cells plus ibrutinib induce CLL remissions
CHICAGO—Chimeric antigen receptor (CAR) T cells combined with ibrutinib enhance T-cell function and can induce complete remission (CR) in patients...